Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration

Vaccine

Volumn 29, Issue 5, 2011, Pages 1017-1022

  Weston, Wayde M ^a   Friedland, Leonard R ^a   Wu, Xiangfeng ^a   Howe, Barbara ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Booster; Diphtheria; Meningococcal; Pertussis; Tetanus; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGOCOCCUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; DIPHTHERIA; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; PERTUSSIS; PRIORITY JOURNAL; SCHOOL CHILD; TETANUS; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; CHILD; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; UNITED STATES;

EID: 78751572803     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.11.057     Document Type: Article

References (20)

1. Broder K.R., Cortese M.M., Iskander J.K., Kretsinger K., Slade B.A., Brown K.H., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-3):1-34.
2. Bilukha O.O., Rosenstein N. Prevention and control of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2005, 54(RR07):1-21.
3. Notice to Readers: Revised recommendations of the advisory committee on immunization practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR 2007; 56(31):794-5.
4. American Academy of Pediatrics Committee on Infectious Diseases Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine. Pediatrics 2006, 117(3):965-978.
5. Schmitt H.J., von König C.H., Neiss A., Bogaerts H., Bock H.L., Schulte-Wissermann H., et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 1996, 275(1):37-41.
6. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996, 334(6):341-348.
7. Centers for Disease Control and Prevention General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006, 55(RR15):1-48.
8. Vitek C.R., Wharton M. Diphtheria toxoid. Vaccines 2008, 139-156. Saunders. 5th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
9. Sato Y., Sato H., Izuma K. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. Seminars in infectious disease: bacteria vaccines 1982, 380-385. Thierne-Stratton, Inc., New York. J.B. Robbins, H.C. Hill (Eds.).
10. Granström M., Thorén M., Blennow M., Tiru M., Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987, 6(1):18-21.
11. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997, 4(2):156-167.
12. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post-licensure surveillance in England. Clin Diag Lab Immunol 2003, 10(5):780-786.
13. Borrow R., Andrews N., Goldblatt D., Miller E. Serological basis for use of meningococcal serogroup C conjugate vaccines for the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001, 69(3):1568-1573.
14. Pichichero M.E., Blatter M.M., Kennedy W.A., Hedrick J., Descamps D., Friedland L.R. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 2006, 117(4):1084-1093.
15. Blatter M., Friedland L.R., Weston W.M., Li P., Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine 2009, 27(5):765-772.
16. Weston W.M., Chandrashekar V., Friedland L.R., Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum Vaccin 2009, 5(12):1-9.
17. Study; [accessed 26.04.10]. http://clinicaltrials.gov/.
18. Arguedas A., Soley C., Loaiza C., Rincon G., Guevara S., Perez A., et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010, 28:3171-3179.
19. Brabin L., Greenberg D.P., Hessel L., Hyere R., Ivanoff B., Van Damme P. Current issues in adolescent immunization. Vaccine 2008, 26(33):4120-4134.
20. Humiston S.G., Rosenthal S.L. Challenges to vaccinating adolescents: vaccine implementation issues. Pediatr Infect Dis J 2005, 24:S134-S140.